University of Vermont
Burlington, Vermont, 05401, United States
NCT Number: NCT00000107
Adults with cyanotic congenital heart disease have elevated levels of plasma proatrial natruretic peptide (proANP) which most likely results in chronic dehydration, leading to reduced oxygen transport to tissues and shortness of breath with activity. The purpose of this study is to characterize adults with cyanotic congenital heart defects with respect to their body composition (water and fat-free mass) and resting metabolic rates. The study consists of several measures of how much body water, fat and lean tissue a subject has, and measures the number of calories the subject's body uses at rest. Adult subjects with cyanotic congenital heart disease will be recruited along with healthy noncyanotic control subjects matched for age, gender, and body weight.
Looking for future studies?
Notify Me17 year–60 year
All sexes
Observational
Burlington, Vermont, 05401, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
National Center for Research Resources (NCRR)
Nih
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07323979
CHD, Cardiovascular Abnormalities
Guangzhou, Guangdong, China
View Trial DetailsNCT04769167
Autoimmune Diseases, Cardiovascular Abnormalities
St Louis, Missouri, United States
View Trial DetailsNCT02987387
Aortic Valve Disease, Cardiovascular Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT06609707
Behavior, Cardiovascular Abnormalities
Cincinnati, Ohio, United States
View Trial Details